Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
By R. Fisher, S. Bernstein, B. Kahl, B. Djulbegovic, M. Robertson, S. de Vos, E. Epner, A. Krishnan, J. Leonard, S. Lonial and 5 more. Journal of Clinical Oncology, 2006
734 citations recorded by the source corpus.
Subfields: Hematology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/866221a4c6bee5b7717ef5c0f7db1c49d9a7a0a8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- C. Gisselbrecht
- B. Coiffier
- M. Frezza
- M. Crump
- S. Schmitt
- Q. Dou
- J. R. Kanwar
- F. Offner
Citations in the corpus
- The role of ubiquitination in tumorigenesis and targeted drug discovery (2020, background): “In tumorigenesis, proteasome abnormalities are not observed; thus, the function of the proteasome in tumor cells may be on the basis of their own needs.11 The boronic acid derivative bortezomib (Velcade, Millennium Pharmaceuticals), a unique first-in-class compound, can slowly and reversibly block c”
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives (2011, background): “However, only about 40 – 50% of mantle cell lymphoma patients and 35% of multiple myeloma patients are sensitive to bortezomib, indicating that up to, or more than half, of patients possess intrinsic resistance to proteasome inhibition, which is a critical limitation of bortezomib therapy [13, 104, ”
- Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. (2009, background): “Bortezomib was evaluated in patients with a maximum of two prior treatments (median, one regimen); a response rate of 33% in 141 assessable patients was observed.(38) Further studies are needed to directly compare the efficacy of these agents with that of temsirolimus in a comparable patient populat”